Hematology/Oncology / Oncology / Hematology/Oncology

Integrating the Latest Evidence on Immune Checkpoint Inhibitors Into the Management of Advanced Non-Small Cell Lung Cancer

CME: 1.0

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Apply biomarker testing results to guide treatment decisions for NSCLC
  • Differentiate treatment options for advanced NSCLC based on clinical safety and efficacy data
  • Integrate clinical evidence and current guideline recommendations on immunotherapies into treatment plans for patients with advanced NSCLC
  • Implement interprofessional strategies for reducing disparities in care access and treatment for NSCLC in rural and underserved settings

Post a comment to this article